四川港通医疗设备集团股份有限公司 第一章 总则 第一条 为规范四川港通医疗设备集团股份有限公司（以下简称公司）募 集资金管理，提高募集资金的使用效率，根据《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司募集资金监管规则》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等相关法律法规、规范性文件以及《四川港通医疗设备集团股份有 限公司章程》（以下简称《公司章程》）的规定，制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他具有股权 性质的证券，向投资者募集并用于特定用途的资金，但不包括公司实施股权激励 计划募集的资金。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产 业政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于 主营业务，有利于增强公司竞争能力和创新能力。 第四条 公司董事会应当持续关注募集资金存放、管理和使用情况，有效 防范投资风险，提高募集资金使用效益。 第五条 公司的董事、高级管理人员应当勤勉尽责，督促公司规范使用募 集资金，确保公司募集资金安全，不得操控公司擅自或变相 ...

Core Points - The Shanghai Composite Index increased by 0.21%, while the CSI All-Industry Medical Index reported at 580.78 points [1] - The CSI All-Industry Medical Index has risen by 2.97% in the past month, decreased by 6.23% over the last three months, and has fallen by 0.83% year-to-date [2] Index Composition - The CSI All-Industry Medical Index is composed of various sectors categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [2] - The top ten weighted stocks in the CSI All-Industry Medical Index are: Mindray Medical (9.47%), Aier Eye Hospital (6.56%), United Imaging (6.25%), Aimeike (2.89%), Huatai Medical (2.67%), New Industry (2.45%), Yuyue Medical (2.44%), Shanghai Pharmaceuticals (2.25%), Yifeng Pharmacy (1.85%), and Meinian Onehealth (1.8%) [2] Market Distribution - The market distribution of the CSI All-Industry Medical Index shows that the Shenzhen Stock Exchange accounts for 56.15%, while the Shanghai Stock Exchange accounts for 43.85% [2] - In terms of industry composition, medical devices represent 29.56%, medical consumables 21.61%, pharmaceutical commerce 18.13%, in vitro diagnostics 17.42%, and medical services 13.28% [2] Index Adjustment - The index samples are adjusted biannually, with adjustments implemented on the next trading day following the second Friday of June and December [3] - Weight factors are generally fixed until the next scheduled adjustment, but can be modified in case of special events affecting the sample companies [3]

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The report highlights that the competition for core talent has intensified, necessitating a shift in recruitment strategies to effectively reach and engage target candidates [7][8] - New media recruitment has emerged as a mainstream method for nearly half of the companies, yet many have not fully leveraged its potential [23][24] - The need for companies to adapt their recruitment teams in response to business innovations and changing talent demands is emphasized [20][30] Summary by Sections Part 1: Business and Recruitment Team Status - Companies are actively seeking new business growth points, with 72.53% indicating a need for business innovation [20][27] - Recruitment team structures are evolving, with 56.05% of companies undergoing significant changes to their recruitment teams [20][28] - Traditional recruitment methods are proving inadequate, with 64.84% of companies unable to effectively reach target candidates [21][58] Part 2: Talent Attraction: Breakthrough Paths in New Media Recruitment - New media recruitment is now a primary method for 50.55% of companies, with WeChat being the most utilized platform [23][24] - Companies face challenges in implementing new media recruitment strategies, particularly in aligning company support and execution methodologies [28][58] - The report suggests that companies need to develop a matrix strategy for selecting appropriate platforms and enhancing user conversion [6][58] Part 3: Talent Activation: Building and Managing Corporate Talent Pools - The construction of talent pools is essential for future talent needs, with 58.24% of companies aiming to build these pools [23][24] - AI technology is being utilized to enhance resume tagging and classification, with 43.91% of companies adopting a combination of human and AI methods for this purpose [23][24] - Companies are focusing on precise talent matching and activation strategies to optimize their recruitment processes [23][24]

Outset Medical (OM) Q1 2025 Conference Call Summary Company Overview - **Company**: Outset Medical (OM) - **Industry**: Medical Devices, specifically focused on dialysis solutions Key Points and Arguments Financial Performance - **Q1 Revenue**: Achieved a 7% upside surprise on revenue, marking the first year-over-year increase in five quarters [3] - **Console Growth**: Console revenue grew approximately 23% sequentially, the first increase in six quarters [3] - **Recurring Revenue**: Strong double-digit growth in recurring revenues, which include consumables and service offerings [4] - **Gross Margin**: Reported gross margin of 37.6%, with expectations to exit the year at around 40% [4][46] Commercial Transformation - **Sales Transformation**: A comprehensive commercial transformation initiated about 18 months ago is showing positive results, with Q1 serving as a proof point [5][38] - **Sales Process Improvements**: New sales processes and leadership have improved the sales pipeline and closing rates [14][15] Market Demand and Value Proposition - **Demand for Tableau**: Strong demand exists for Tableau, which saves hospitals money by allowing them to insource dialysis services [7][8] - **Cost Savings**: Hospitals can see payback on Tableau investments within a year, with significant cost savings compared to outsourcing [22][24] Pipeline and Growth Metrics - **Pipeline Health**: The company is pleased with the composition and growth of its sales pipeline, which has seen growth in both Q4 and Q1 [12] - **Installed Base**: The current installed base is expected to generate approximately $500 million in recurring revenues over the coming years [30] Operational Insights - **Field Service Team**: Investments are being made in the field service engineering team to enhance customer satisfaction, which currently stands at over 90% [35] - **Remote Diagnostics**: Investments in remote repair and diagnostics are expected to improve service efficiency [36] Guidance and Future Outlook - **Conservative Guidance**: Despite a strong Q1, the company has chosen not to raise its guidance, opting for a conservative approach [39][41] - **Long-term Goals**: Aiming for adjusted EBITDA positivity at less than $200 million in sales, with a focus on achieving 50% gross margins [52][53] Market Penetration - **Acute Market Penetration**: Currently about 10% penetrated in the acute market, with significant room for growth [67] - **Home Market**: Only 1,500 consoles sold into the home market against a potential 600,000 chronic patients, indicating early-stage market penetration [68] Strategic Focus - **US Market Focus**: The company is primarily focused on the US market, which has a total addressable market (TAM) of $11 billion [62] - **Potential Partnerships**: While open to partnerships, the current strategy emphasizes capitalizing on existing market opportunities [64] Additional Important Insights - **Clinical Benefits**: Insourcing with Tableau has led to significant clinical improvements, including a 75% reduction in infection rates in some hospitals [25] - **Customer Engagement**: A large reference account list is available to assist prospects in decision-making [26] This summary encapsulates the key insights from the Outset Medical Q1 2025 conference call, highlighting the company's financial performance, market strategies, and future outlook.

来源：弈赫市场咨询 北京弈赫国际信息咨询有限公司是一家业务覆盖全球的利基市场信息咨询公司，研究涉及了21个主要行业和1200个利基市场，覆盖了70多个国 家，一直致力于产出专业严谨的行业趋势分析，数据洞察，市场研究和解决方案。百度搜索yiheconsult或者弈赫咨询，访问官网获得免费报告样 本。 北京弈赫市场咨询最近发布了关于X射线检查系统2025市场深度分析报告，包括全球与中国版本。作为专业的市场研究机构，我们行业跟踪多年，并能够根 据客户需求进行定制化分析。想要了解行业最新动态的读者可申请获得免费样本。 2025年X射 复合年增长率 (2025-2030) $XX(申请免费样本获得市场规 模数据) 本报告主要面向医疗设备制造商、医院运营管理者、医疗政策制定者和投资者等专业人士。对于医疗行业的从业者而言，了解X射线检查系统的市场动态和 发展趋势至关重要。报告不仅分析了市场规模与增长预测，还对关键参与者的竞争策略进行了详细解读，为读者提供了深刻的市场洞察。此外，随着X射线 技术的不断演进，相关法规与政策的变动也会对行业产生深远影响，因此，阅读本报告能够帮助受众在迅速变化的市场环境中做出更明智的决策。 在全球 ...

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Viewpoints - The report highlights that President Trump plans to sign an executive order to reduce prescription drug prices in the U.S. by 30% to 80%, which is expected to benefit domestic CXO companies [4][5] - The pharmaceutical sector saw an overall increase of 1.27% this week, with most sub-sectors showing positive performance [15][22] - The report emphasizes the potential for domestic companies to reshape their valuations and market opportunities in light of U.S. drug pricing reforms [5][14] Summary by Sections Weekly Insights - President Trump announced plans to lower U.S. prescription drug prices significantly, which could positively impact the domestic CXO industry [4][13] - The pharmaceutical sector's performance this week was characterized by a 1.27% increase, outperforming the CSI 300 index by 0.16 percentage points [17][23] Sub-sector Performance - The raw materials sector had the highest increase at 3.79%, followed by the IVD sector at 2.25% and the vaccine sector at 1.98% [6][22] - The report notes that the medical device sector is expected to see significant growth due to upcoming procurement policies and a favorable market environment [25] Recommended and Beneficiary Stocks - Recommended stocks include Weikang Medical, Maipu Medical, and Yingke Medical, among others [7][29] - Beneficiary stocks include Huada Gene, Yidu Technology, and Mindray Medical, which are expected to perform well under current market conditions [27][42] Market Trends - The report indicates that the medical services sector is experiencing a slight increase, with hospitals showing a 0.10% rise this week [37] - The traditional Chinese medicine sector is also seeing growth, with a 1.73% increase attributed to improved profit margins and reduced sales expenses [39] Regulatory and Policy Impacts - The report discusses the implications of U.S. drug pricing reforms on global pharmaceutical supply chains and the increased reliance on CXO companies for cost control [5][14] - It also highlights the potential for AI and technology integration in the healthcare sector, which could enhance operational efficiencies and market competitiveness [28][41]

Core Points - Beijing has issued a comprehensive implementation plan to accelerate the construction of a unified national market, focusing on addressing urgent issues raised by the public and market entities [1][3] - The plan includes 55 specific tasks across six areas, emphasizing the removal of market access barriers and the establishment of a standardized regulatory framework [1][3] Group 1: Market Access and Regulation - The implementation plan aims to clean up market access barriers and establish a negative list for market entry, ensuring that anything not prohibited is allowed [3] - A green channel for major patent infringement disputes will be established, along with the release of guidelines for overseas intellectual property rights protection [3] - The plan includes a comprehensive review of 2,247 local standards to eliminate those that restrict competition [6] Group 2: Data and Technology - Beijing will promote a national integrated data market and explore a model for data products that allows for "one location listing, local mutual recognition" [4][5] - The city has opened 18,000 public datasets to society, enhancing the availability of high-quality data for various applications [2] Group 3: Standardization and Fair Competition - The city will implement measures to align local standards with international practices, particularly in service quality and product certification [6] - A focus on fair competition will be maintained through the establishment of a transparent review process for local policies and regulations [3][6] Group 4: Open Collaboration and Cross-Regional Cooperation - The plan emphasizes the importance of open collaboration, aiming to facilitate cross-regional cooperation in areas such as administrative services and credit regulation [7][8] - Specific initiatives include the mutual recognition of qualifications and the establishment of a unified platform for cross-border trade facilitation [8]

从主力资金连续性进行观察，共有61只个股主力资金连续3个交易日以上持续净流入，连续净流入天数 最多的是瑞联新材、利扬芯片等2只股，主力资金均连续净流入11天。主力资金连续流出的个股有153 只，连续流出天数最多的是先锋精科，该股已连续23个交易日净流出；连续净流出天数较多的还有三达 膜、嘉元科技等，主力资金分别连续流出13天、11天。（数据宝） 主力资金净流入排名 | 代码 | 简称 | 主力资金净流入（万元） | 主力资金流入率（%） | 涨跌幅（%） | 换手率（%） | | --- | --- | --- | --- | --- | --- | | 688297 | 中无人机 | 10605.92 | 9.38 | 5.61 | 8.97 | | 688256 | 寒武纪 | 9228.28 | 4.15 | 0.59 | 0.80 | | 689009 | 九号公司 | 6284.70 | 10.20 | 2.35 | 1.73 | | 688052 | 纳芯微 | 5770.61 | 13.59 | -0.28 | 1.65 | | 688755 | C汉邦 | 5350.65 | 14.63 | ...

Group 1 - The third Advanced Technology Achievement Transformation Conference took place in Suzhou, showcasing over 1,500 companies across various industry clusters [1] - A micro drone resembling a thermos was displayed by Suzhou Lanjun Technology, capable of being controlled by a ground station to perform inspection and photography tasks [1] - AI glasses designed for the visually impaired were presented, featuring radar obstacle avoidance and real-time voice broadcasting capabilities [2] Group 2 - A digital gait assessment and training robot was introduced by Guanyi Medical, integrating AI and virtual reality to analyze gait data and assist in rehabilitation [2] - A nuclear technology application for kitchen waste resource utilization was demonstrated by Zhongke Tongchuang, converting organic waste into organic fertilizer efficiently [3]

Group 1: GE Healthcare and Precision Medicine - GE Healthcare's China Precision Medicine Industrial Base Phase I has been completed, promoting the localization of high-end equipment and innovation in precision medicine [5] - The project focuses on the production of key nuclear medicine imaging equipment, specifically cyclotrons, to drive innovation in the precision medicine industry chain [5] - GE Healthcare plans to enhance investment in talent, technology, and scale in Sichuan, expanding production lines to cover the entire nuclear medicine imaging chain [5] Group 2: Ruixing Jiuyu Gas Equipment - Ruixing Jiuyu Gas Equipment's new R&D center in Chengdu is set to be operational next month, aimed at upgrading gas equipment products and enhancing market share [4][6] - The R&D center, covering approximately 3,000 square meters, will feature advanced equipment such as 3D printers and performance testing platforms [6] - The company has committed to investing 5% of its annual sales revenue into product R&D to strengthen its core competitiveness [6] Group 3: Guoyao Tianyu Zhigu Project - The Guoyao Tianyu Zhigu project, with a total investment of 3 billion yuan and covering 163 acres, has officially commenced construction [7] - This project is the first third-generation smart industrial park established by Guoyao Group in Southwest China, focusing on healthcare, electronic information, equipment manufacturing, and new materials [7] - The project aims for overall delivery by mid-2027 and will include talent apartments and a supply chain finance center to create an integrated ecosystem [8]